KLINGEL MEDICAL GROUP acquired by ELOS MEDTECH

Oakley Capital, through its Fund V, has successfully finalized the acquisition of Flemming Dental, Excent, and Artinorway Group in a strategic carve-out from European Dental Group (EDG). This transaction consolidates three major regional players to form one of the premier independent dental laboratory groups in Europe. The strategic rationale for the move centers on the high degree of fragmentation in the European dental lab market, which presents significant opportunities for value creation through a disciplined buy-and-build strategy. By separating these entities from a broader services provider, the group aims to establish an independent technical leader focused exclusively on the accelerating digitalization of the prosthetic and orthodontic sectors. The partnership focuses on leveraging the acquirer’s expertise in technological innovation and international expansion to scale the group’s existing network across European borders. This integration is designed to accelerate the adoption of cutting-edge CAD/CAM and 3D printing technologies, enhancing precision and delivery speed for its combined base of clinics. This transaction reinforces the group’s standing as a primary enabler of the digital transformation within the oral care supply chain, providing the strategic depth required to achieve global market leadership.

Eurazeo has completed the sale of D.O.R.C. to Carl Zeiss Meditec AG. This transaction marks the successful conclusion of a four-year transformation under Eurazeo's ownership, during which D.O.R.C. evolved from a European champion into a global platform. The strategic rationale for Zeiss is to create a comprehensive "end-to-end" offering for ophthalmologists. By integrating D.O.R.C.'s leading vitreoretinal surgical systems with Zeiss's existing portfolio of diagnostics, microscopes, and digital workflows, the combined entity becomes a one-stop-shop for eye care providers. The deal also unlocks significant cross-selling opportunities, leveraging Zeiss's massive global distribution network to accelerate the adoption of D.O.R.C.'s products in under-penetrated markets.

EQT completed the take-private acquisition of Dechra Pharmaceuticals. The strategic rationale for taking Dechra private was to support its long-term growth away from the volatility of public markets. In early 2023, Dechra faced headwinds from "wholesaler de-stocking" in the US, which hit its share price. EQT intends to accelerate investment in the company's innovation pipeline and support further international acquisitions without the pressure of quarterly earnings reporting.

Lauxera Capital Partners has successfully led a £25 million growth investment into OrganOx, marking a pivotal minority platform entry into the high-barrier medical technology sector. Based in Oxford, England, the commercial-stage enterprise represents a strategic addition to the investor's specialized healthcare portfolio. The investment thesis centers on funding the global scale-up and commercial acceleration of an established, market-leading medical device platform. OrganOx leverages a proprietary technology, normothermic machine perfusion, which has already supported over 2,500 liver transplants worldwide. The strategic rationale of the capital injection is focused on rapidly expanding OrganOx's commercial footprint and deeply institutionalizing its partnerships with tier-one transplant centers across the United States and Europe.

The acquisition of Biocorp by Novo Nordisk, achieved through the purchase of Bio Jag's 45.3% stake and a subsequent mandatory public tender offer, marks a significant shift in strategy, transitioning from a collaborative research and development model to a proprietary technology platform. Having previously mitigated risks associated with the Mallya technology through regulatory approvals and commercial validation, including agreements with prominent industry players such as Sanofi and Roche Diabetes Care, Biocorp's management had laid the groundwork for this transaction. By assuming full ownership, Novo Nordisk gains control over a crucial component of its supply chain, securing exclusive access to a key connectivity solution for pen injectors. Under the continued leadership of CEO Éric Dessertenne, the integration process prioritizes the expansion of physical assets, notably the launch of an enlarged manufacturing facility in Issoire, aimed at increasing production capacity. The growth strategy following the acquisition is centered on leveraging Novo Nordisk's extensive global distribution network to deploy connected delivery systems on a large scale, while repurposing the French manufacturing hub as a specialized development center for next-generation digital monitoring devices across a broader range of therapeutic areas, with plans to enter new markets and expand product offerings.

The successful acquisition of AprioMed by IZI Medical Products represents a tactical expansion of Halma’s healthcare portfolio in the interventional radiology segment. This transaction marks the integration of AprioMed’s highly specialized bone biopsy technology, effectively widening the technical operational depth available to IZI Medical’s global clinical customer base. The strategic rationale centers on the industrial synergy between AprioMed’s minimally invasive instruments and IZI Medical’s established oncology and radiology portfolio, allowing for a more verticalized patient diagnosis solution. By incorporating AprioMed, IZI Medical reinforces its ability to address the increasing demand for cancer diagnosis tools driven by an aging global population. The partnership is designed to leverage IZI Medical’s existing global distribution channels and direct international presence to drive the scaling of AprioMed’s proprietary hardware. This integration facilitates a more robust clinical platform, providing the strategic depth required to navigate the complex evolution of the global healthcare landscape. The move solidifies the group’s standing as a primary enabler of diagnostic precision and manufacturing excellence.

Sartorius Stedim Biotech has reached a definitive agreement to acquire one hundred percent of the share capital of Polyplus from private equity sponsors ArchiMed and Warburg Pincus. This landmark transaction is structured as a full buyout, effectively transferring ownership from financial sponsors to a strategic corporate acquirer. The operation is financially underpinned by a bridge loan facility secured by the acquirer's parent company through J.P. Morgan, which is expected to be ultimately refinanced via long-term financial instruments potentially incorporating an equity component. This platform investment represents a highly synergistic and value-accretive maneuver for the acquirer, structurally designed to capture a significant share of the rapidly expanding cell and gene therapy market. The acquisition introduces vital technological complementarities, specifically bridging the target's pioneering expertise in viral vector production components with the acquirer’s established portfolio of cell culture media and advanced therapy essentials. By internalizing these capabilities, the acquirer strengthens its footprint in the United States while capitalizing on a sector characterized by high structural growth and accelerating pipeline developments. The financial parameters of the transaction underscore the premium nature of the target asset, driven by an intensively competitive environment wherein proactive industrial consolidators rapidly outpaced financial sponsors during the preemptive phase of the process. The deal delivers an exceptional exit profile for the incumbent sponsors, culminating in an impressive multiple on invested capital realized over the investment holding period.

Ardian has acquired a stake in Théradial, a specialized player in the French dialysis sector, with a consolidated presence in medical product distribution, pharmaceuticals, and healthcare software. This transaction is part of a strategic partnership with UI Investissement, which had previously invested in the company in 2017. Founded in 1998, Théradial employs around 90 staff in France and Italy, generating approximately 50 million euros in revenue, primarily from public healthcare establishments, private clinics, and home care service providers. Ardian's strategy aims to structure Théradial's growth, notably through organic development of its medical product activities and targeted acquisitions. This operation will enable Théradial to strengthen its market positioning and accelerate its development, particularly in nutrition and digital division, with the objective of entering new markets and diversifying its activities. The Ardian Growth team, led by Alexis Saada and Frédéric Quéru, will work closely with Théradial's management to implement this growth strategy, focusing on increasing revenue and improving the company's profitability. This operation is also expected to allow Théradial to consolidate its relationships with clients and suppliers, and reinforce its position in the French and Italian dialysis markets, with a view to expanding its customer base and enhancing its operational efficiency.

Unither Pharmaceuticals, a global leader in sterile single-unit dosage manufacturing, has undergone a capital reorganization led by its management team and a consortium of prominent investors. GIC and IK Partners have entered as new equity partners, while Keensight Capital and Parquest are reinvesting to reinforce their existing positions. The consortium is acquiring the majority stake from Ardian, following a successful five-year partnership.

Stanley Capital Partners acquired a majority stake in Laboratoire X.O following the liquidation of its former owner, Novalpina Capital. The deal resolved a year-long legal dispute between management and transitional managers (BRG). This new phase focuses on a strategic merger with Noden Pharma (another SCP portfolio company), providing X.O with a commercial platform in Ireland and the United States. The goal remains to triple revenue within 3-4 years through aggressive portfolio acquisitions.